EP2265590A4
(en )
2012-04-25
Selective inhibitors of histone deacetylase
HK1220179A1
(en )
2017-04-28
Inhibitors of histone deacetylase
EP2217588A4
(en )
2013-12-04
Inhibitors of histone deacetylase
ZA200906609B
(en )
2010-05-26
Inhibitors of histone deacetylase
HK1142597A1
(en )
2010-12-10
Inhibitors of histone deacetylase
ZA201207856B
(en )
2013-06-29
Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
EP2451790A4
(en )
2012-12-26
Histone deacetylase inhibitors
ZA201206063B
(en )
2023-05-31
Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2170076A4
(en )
2011-09-07
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP1991226A4
(en )
2012-01-25
Inhibitors of histone deacetylase
IL205241A0
(en )
2010-12-30
Histone deacetylase inhibitors
HK1128285A1
(en )
2009-10-23
Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
HK1166245A1
(en )
2012-10-26
Composition for improving taste of high-intensity sweetener and application thereof
ZA201109030B
(en )
2013-02-27
Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase,preparation methods and uses thereof
HUE046932T2
(en )
2020-04-28
Arginase inhibitors and methods of use
PT2680694T
(en )
2019-03-14
Histone deacetylase inhibitors
IL214244A
(en )
2017-07-31
Histone deacetylase inhibitors and their use in therapy
IL227379A0
(en )
2013-09-30
Histone deacetylase inhibitors and compositions and methods of use thereof
EP2308868A4
(en )
2013-01-16
Histone deacetylase inhibitors and uses thereof
EP2393787A4
(en )
2012-11-28
Cadherin-11 inhibitors and methods of use thereof
EP2231596A4
(en )
2012-06-06
Histone deacetylase inhibitors
EP2205563A4
(en )
2012-01-25
Novel histone deacetylase inhibitors
RS58895B1
(en )
2019-08-30
Pharmaceutical formulation for histone deacetylase inhibitors
ZA201001972B
(en )
2012-06-27
Novel teteahydrofusedpyridines as histone deacetylase inhibitors
PT2344253E
(en )
2014-07-16
Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes